Why Women With Metastatic Triple Negative Breast Cancer Cannot Wait
The median survival for metastatic triple negative breast cancer is 13.6 months.
Not years. Barely over a year.
When you're looking at a 13-month window, every single month matters. If a promising therapy is delayed six months in development or regulatory review, that represents nearly half of a patient's remaining life.
I'm not talking about theoretical future benefits. I'm talking about whether someone gets to see their daughter's graduation or their son's wedding.
The math is brutal and unforgiving.
Each month of delay isn't just a statistic. It's birthdays missed, conversations never had, and families losing mothers, daughters, and sisters who might have had more time with access to promising treatments that are sitting in regulatory limbo.
The Data That Shouldn't Be Waiting
Leronlimab, a CCR5 targeting antibody now in Phase 2 development, has shown something compelling in early trials.
A favorable safety profile combined with signals of efficacy, particularly when combined with checkpoint inhibitors like carboplatin.
The Phase 2 data showed we weren't seeing the typical severe adverse events you often get with aggressive cancer treatments. The drug was well-tolerated—only 1 out of 68 total adverse events was grade III and related to leronlimab.
That matters enormously for quality of life in these patients.
But more importantly, there were indications of disease stabilization and potential life extension in a patient population where standard options have essentially failed.
A pooled analysis showed that patients with lower levels of circulating cells following leronlimab treatment demonstrated a 3,600% increase in overall survival at 12 months compared to standard of care. Patients treated with higher doses had median overall survival exceeding 12 months.
For women with metastatic triple negative breast cancer who've exhausted other options, even a few additional months of stable disease with decent quality of life is significant.
The combination approach showed particular promise because it seemed to work synergistically with existing therapies rather than requiring patients to abandon what might still be providing some benefit.
What frustrates me is that this data, while early-stage, represents real hope for a population that has almost none. Yet the pathway to get this therapy into patients' hands feels impossibly long given their survival timeline.
Two Companies, Two Completely Different Pathways
If Pfizer had this Phase 2 data, they'd have teams of regulatory experts immediately mapping out the fastest pathway—whether that's breakthrough designation, accelerated approval, or priority review.
They'd have the resources to run multiple parallel trials, hire the top clinical research organizations, and have regular meetings with FDA officials to ensure their trial designs meet every requirement.
Their name alone opens doors at the FDA.
For a company like CytoDyn, it's a completely different reality.
They're working with limited capital, which means they can't afford to run large, expensive Phase 3 trials simultaneously. They're often figuring out regulatory strategy as they go, sometimes making costly mistakes because they don't have a bench of former FDA officials on staff.
When they request meetings with the FDA, they might wait months for a response that a larger company gets in weeks.
The trial designs they can afford might not be the gold standard the FDA wants, but it's what their budget allows.
And here's the thing: even if the science is equally promising, a smaller company faces skepticism.
There's an implicit bias that if this were really groundbreaking, a big player would have picked it up.
CytoDyn is stuck in this catch-22: they need more data to attract partnership or funding, but they need funding to generate that data.
Meanwhile, the clock is ticking for patients who could potentially benefit right now.
When the Pattern Becomes Lethal
I haven't seen a smoking gun document that says "we're rejecting this because you're small," but the pattern is undeniable when you look at the data.
There was a case a few years back with a small company developing a therapy for a rare pediatric cancer. They had Phase 2 data showing remarkable responses—kids who were supposed to have weeks were getting months, some even a year or more.
But they couldn't get expedited review because the FDA wanted a larger dataset. The company literally couldn't afford to enroll enough patients quickly.
Meanwhile, a major pharmaceutical company got accelerated approval for a different cancer therapy with a similar sample size and response rate within 18 months.
The small company took over four years.
By the time their therapy was approved, some of the children who could have been in early access programs had already died. Their parents testified about it later.
That's when the bias becomes lethal—it's not active malice, it's structural indifference.
The system isn't designed to ask "how do we get this to dying patients faster?" It's designed to ask "does this meet our standard process?"
And when you're small, you don't have the leverage to push back on that process or the resources to meet every demand simultaneously.
The assumption that "real" innovations come from big companies becomes a self-fulfilling prophecy because only big companies can navigate the system efficiently enough to prove their innovations work within patients' survival windows.
What a Survival-Based Urgency Pathway Would Look Like
The biggest change would be creating a separate expedited track specifically for terminal diagnoses where patients have exhausted standard options.
Here's what that would look like:
First: If you can demonstrate in Phase 2 that your therapy has a favorable safety profile and any signal of efficacy in a population with less than 18 months median survival, you get automatic fast-track designation regardless of company size.
Second: The FDA would assign a dedicated case manager to smaller companies, just like they do for major pharmaceutical players, to provide real-time guidance and prevent costly trial design mistakes.
Third: We'd shift the burden of proof for terminal patients. Instead of requiring companies to prove beyond doubt that the therapy works before any access, we'd allow conditional approval based on safety and preliminary efficacy, with the requirement to continue gathering data post-approval.
The key is recognizing that for someone with 13 months to live, the risk-benefit calculation is fundamentally different than for someone with a chronic but manageable condition.
Right now, we're applying the same standard of caution to both.
A terminal patient isn't choosing between a new therapy and perfect health—they're choosing between a new therapy and certain death.
The pathway should reflect that reality.
We'd also need mandatory response timelines—if the FDA doesn't respond to a small company's submission within 30 days for a terminal diagnosis therapy, it gets automatic escalation to senior leadership.
No more months-long waits that eat up half a patient's remaining life.
When Caution Becomes Harm
Caution becomes harm the moment it prioritizes theoretical future risks over the certainty of imminent death.
I understand the FDA's perspective—they're haunted by historical disasters like thalidomide. But we need to be honest about what we're actually protecting terminal patients from.
If someone has 13 months to live and we deny them access to a therapy with a favorable safety profile because we're worried it might only extend life by two months instead of six, or because we need another year of data to be absolutely certain—we haven't protected that patient.
We've condemned them.
They're dead either way, but in one scenario they had hope and possibly more time, and in the other they had neither.
The FDA's caution made sense when it was developed—it was designed to protect healthy people or those with manageable chronic conditions from being harmed by inadequately tested drugs.
But applying that same framework to someone who is dying creates a perverse outcome.
We're essentially saying, "We'd rather you die on schedule from your disease than risk dying slightly earlier from a therapy that might have saved you."
That's not protection. That's abandonment dressed up as prudence.
And here's what really bothers me: we already accept this logic in other contexts. We allow terminal patients to try experimental therapies through compassionate use, acknowledging that their situation is different.
But we make it so difficult, so case-by-case, that most patients never access it.
Why not systematize that recognition?
The Compassionate Use Nightmare
The reality is it's a bureaucratic nightmare that most patients don't have time for.
First, the patient's physician has to be willing to request it, which many aren't because of liability concerns or simply not knowing the process exists.
Then the company—in this case CytoDyn—has to agree to provide the drug, which for a small biotech with limited supply is a real resource question. They're trying to manufacture enough for their clinical trials, and every compassionate use case depletes that inventory.
Then you need FDA approval for single-patient access, which requires submitting an Investigational New Drug application. Even on the "emergency" track, this can take weeks.
For someone with 13 months median survival who's already exhausted standard treatments, weeks matter enormously.
But here's the cruelest part: even if you get through all that, insurance won't cover it.
The patient needs either the company to provide it free—which small biotechs often can't afford to do at scale—or the family has to pay out of pocket for the drug plus all the associated medical care and monitoring.
We're talking tens of thousands of dollars that most families don't have.
I've seen cases where patients got approval for compassionate use but couldn't actually access the therapy because of cost. You jump through all these hoops, you get the FDA to say yes, and then you still can't get the treatment.
The system is designed for exceptional cases, not as a real pathway. It's essentially a PR mechanism that lets us say "options exist" while ensuring those options remain practically inaccessible to most dying patients.
That's why we need systematic reform, not just compassionate use Band-Aids.
The Resource Gap Changes Everything
If CytoDyn had Pfizer-level resources tomorrow, we'd be looking at a completely different timeline—probably 18 to 24 months to potential approval instead of the 4 to 6 years they're currently facing.
Here's what would change immediately:
They could launch multiple Phase 3 trials simultaneously in different countries, enrolling patients much faster. Instead of scraping together funding for one trial at a time, they'd run parallel studies—one for Leronlimab as monotherapy, another for combination with checkpoint inhibitors, maybe a third exploring different dosing schedules.
That parallel approach alone cuts years off development time.
They'd hire a top-tier clinical research organization that knows exactly how to design trials the FDA wants to see the first time—no costly do-overs or protocol amendments that add months.
They'd have former FDA officials on staff who could pick up the phone and get guidance in days, not months.
They'd be running adaptive trial designs that allow them to adjust in real-time based on interim data, which the FDA is more comfortable with when you have the infrastructure to do it properly.
Most importantly, they'd have the manufacturing capacity to supply both clinical trials and a robust compassionate use program simultaneously.
Patients wouldn't have to choose between trial enrollment and individual access. They could also fund patient assistance programs to cover costs that insurance won't.
The science wouldn't change—Leronlimab's mechanism and the Phase 2 data would be exactly the same.
But the infrastructure, expertise, and financial runway to prove it definitively would compress that timeline by years.
And for women with 13-month median survival, those years are everything.
That's the inequity we're dealing with—promising science held hostage by resource constraints.
Why Big Pharma Hasn't Partnered
Big Pharma doesn't partner based solely on scientific merit—they partner based on risk-adjusted return on investment.
There are several factors working against a company like CytoDyn that have nothing to do with Leronlimab's actual potential.
First, CytoDyn has had management and execution challenges that make them a less attractive partner, regardless of their drug's promise. Big Pharma wants clean, well-executed trials and clear regulatory pathways.
If a small company has stumbled—missed endpoints, had leadership turnover, faced SEC issues—that creates partnership risk that has nothing to do with the molecule itself.
It's like refusing to buy a house with great bones because the previous owner was a messy renovator.
Second, metastatic triple negative breast cancer, while devastating, is still a relatively small market compared to blockbuster indications. Big Pharma is often looking for billion-dollar opportunities.
A therapy that might extend life by several months for a few thousand patients annually doesn't move the needle for a company doing $50 billion in revenue, even if it's transformative for those individual patients.
Third—and this is cynical but true—Big Pharma often waits for smaller companies to de-risk assets further before acquiring them.
Why pay for Phase 2 uncertainty when you can wait until Phase 3 data is in and acquire the company for less than it would cost if you factor in their desperation for capital?
It's a calculated strategy that makes business sense but leaves patients waiting.
The lack of partnership doesn't mean the science is flawed—it means the business case hasn't aligned yet.
And while those calculations are happening in boardrooms, women are dying.
Company Mistakes vs. Systemic Problems
It's both, and that's what makes this so complicated.
CytoDyn has absolutely made missteps—trial designs that didn't meet FDA expectations, communication issues with regulators, leadership decisions that raised eyebrows. Those are real problems that have delayed Leronlimab's development.
If they'd had better regulatory guidance from the start, we'd probably be further along.
But here's the thing: those missteps are often symptoms of the systemic problem, not separate from it.
When you're a small biotech operating on a shoestring budget, you can't afford the expertise that prevents those mistakes. You're making critical regulatory decisions without the benefit of former FDA officials who know exactly what the agency wants to see.
You're designing trials with limited capital, which means you might cut corners that come back to haunt you.
You're under constant pressure from investors to show progress, which can lead to overpromising or pivoting strategies too quickly.
It's like asking someone to perform surgery with inadequate training and dull instruments, then blaming them when the outcome isn't perfect.
A well-resourced company would have avoided many of CytoDyn's specific mistakes, but they'd still face the fundamental barriers—slower FDA response times, limited trial capacity, skepticism about their legitimacy.
The difference is they'd navigate those barriers more efficiently.
CytoDyn's challenges are partly self-inflicted, but the system created the conditions where those mistakes become fatal to the drug's development timeline.
A more equitable system would have safeguards to prevent promising therapies from being derailed by correctable company-level problems.
Right now, we let the therapy die with the company's mistakes, and patients pay the price.
A Therapeutic Rescue Mechanism
This would require creating what I'd call a "therapeutic rescue mechanism" within the FDA framework.
Here's how it would work:
When a therapy shows genuine promise in early trials—favorable safety profile, signals of efficacy in a serious or terminal condition—but the developing company is struggling with execution, the FDA would have authority to essentially put the asset into a form of regulatory receivership.
They'd facilitate transfer of the Investigational New Drug application to a qualified partner—either a larger pharmaceutical company, a specialized clinical research organization, or even a consortium of academic medical centers—who could take over development while compensating the original company fairly for their investment.
The key is that the therapy's development wouldn't be held hostage to one company's operational challenges.
We'd need clear triggers: maybe if a company misses critical trial endpoints twice due to design flaws, or if they can't secure funding to continue development within a certain timeframe for a designated breakthrough therapy.
At that point, the FDA could broker a transition.
This isn't about punishing small companies—it's about recognizing that patients' lives are more important than any single company's exclusive rights to develop a molecule.
Think of it like eminent domain for promising therapies in terminal diseases.
Yes, it would be controversial and we'd need strong protections against abuse, but right now we're prioritizing property rights over human lives.
If Leronlimab truly has potential to help women with metastatic triple negative breast cancer, it shouldn't matter whether CytoDyn executes perfectly—what should matter is getting that therapy evaluated properly and into patients' hands.
The current system treats the therapy and the company as inseparable, and that's a fatal flaw when time is measured in months of survival.
The Innovation Incentive Argument
That argument assumes the current system is actually incentivizing the right behavior, and I'd challenge that assumption hard.
Right now, we're incentivizing companies to hold onto assets they can't adequately develop, hoping to eventually sell them at a premium or stumble into a partnership.
That's not innovation. That's speculation.
Real innovation is getting therapies to patients who need them.
I'm not suggesting we seize assets arbitrarily or without fair compensation. This would only apply to therapies for serious or terminal conditions where the company has demonstrably failed to advance development despite showing early promise, and only after clear opportunities to correct course.
We'd build in protections—maybe the original company retains royalty rights, or gets first right of refusal to partner before any transfer happens.
The goal isn't to punish risk-taking. It's to ensure that when someone takes a risk and discovers something valuable, that value reaches patients rather than dying in developmental limbo.
And here's the thing about innovation incentives: the biggest disincentive to biotech investment right now is watching promising therapies fail not because the science was wrong, but because the company couldn't navigate the regulatory and financial maze.
Investors lose everything when that happens.
A rescue mechanism would actually protect investment by ensuring promising assets don't become total losses due to execution failures. You'd still get your return, just through a different structure.
The real question is: what are we optimizing for?
If we're optimizing for maximum company autonomy and property rights, then yes, this is radical.
But if we're optimizing for getting life-saving therapies to dying patients as quickly as possible, then letting promising drugs languish because we're afraid of disrupting business models is the truly radical position.
We've just normalized it.
What Should Happen in the Next Six Months
In the next six months, three things should happen that would make a tangible difference for patients running out of time today.
First, the FDA should grant Leronlimab breakthrough therapy designation for metastatic triple negative breast cancer. The existing Phase 2 data showing favorable safety and survival signals in a population with 13-month median survival meets the criteria. This designation would provide more frequent FDA guidance and potentially accelerate the approval timeline.
Second, CytoDyn should establish an expanded access program that goes beyond traditional compassionate use. Partner with patient advocacy groups and academic medical centers to create a structured pathway for patients who've exhausted standard options to access Leronlimab while contributing to the data collection needed for approval. Make it systematic, not exceptional.
Third, the FDA should assign a dedicated case manager to CytoDyn's Leronlimab program—the same level of support given to major pharmaceutical companies. This would prevent costly trial design mistakes, accelerate regulatory feedback loops, and ensure the company isn't navigating the approval process blind.
None of these require changing laws or creating new regulatory frameworks. They require recognizing that for women with metastatic triple negative breast cancer, six months represents nearly half their remaining life.
The system can move faster when it chooses to.
The question is whether we value procedural consistency more than we value giving dying patients a chance.
Because right now, while we're debating timelines and trial designs and partnership strategies, women are losing time they'll never get back.
Time with their families. Time to try a therapy that might give them more birthdays, more conversations, more moments.
That's not theoretical. That's happening right now.
The median survival for metastatic triple negative breast cancer is 13.6 months.
Not years. Barely over a year.
When you're looking at a 13-month window, every single month matters. If a promising therapy is delayed six months in development or regulatory review, that represents nearly half of a patient's remaining life.
I'm not talking about theoretical future benefits. I'm talking about whether someone gets to see their daughter's graduation or their son's wedding.
The math is brutal and unforgiving.
Each month of delay isn't just a statistic. It's birthdays missed, conversations never had, and families losing mothers, daughters, and sisters who might have had more time with access to promising treatments that are sitting in regulatory limbo.
The Data That Shouldn't Be Waiting
Leronlimab, a CCR5 targeting antibody now in Phase 2 development, has shown something compelling in early trials.
A favorable safety profile combined with signals of efficacy, particularly when combined with checkpoint inhibitors like carboplatin.
The Phase 2 data showed we weren't seeing the typical severe adverse events you often get with aggressive cancer treatments. The drug was well-tolerated—only 1 out of 68 total adverse events was grade III and related to leronlimab.
That matters enormously for quality of life in these patients.
But more importantly, there were indications of disease stabilization and potential life extension in a patient population where standard options have essentially failed.
A pooled analysis showed that patients with lower levels of circulating cells following leronlimab treatment demonstrated a 3,600% increase in overall survival at 12 months compared to standard of care. Patients treated with higher doses had median overall survival exceeding 12 months.
For women with metastatic triple negative breast cancer who've exhausted other options, even a few additional months of stable disease with decent quality of life is significant.
The combination approach showed particular promise because it seemed to work synergistically with existing therapies rather than requiring patients to abandon what might still be providing some benefit.
What frustrates me is that this data, while early-stage, represents real hope for a population that has almost none. Yet the pathway to get this therapy into patients' hands feels impossibly long given their survival timeline.
Two Companies, Two Completely Different Pathways
If Pfizer had this Phase 2 data, they'd have teams of regulatory experts immediately mapping out the fastest pathway—whether that's breakthrough designation, accelerated approval, or priority review.
They'd have the resources to run multiple parallel trials, hire the top clinical research organizations, and have regular meetings with FDA officials to ensure their trial designs meet every requirement.
Their name alone opens doors at the FDA.
For a company like CytoDyn, it's a completely different reality.
They're working with limited capital, which means they can't afford to run large, expensive Phase 3 trials simultaneously. They're often figuring out regulatory strategy as they go, sometimes making costly mistakes because they don't have a bench of former FDA officials on staff.
When they request meetings with the FDA, they might wait months for a response that a larger company gets in weeks.
The trial designs they can afford might not be the gold standard the FDA wants, but it's what their budget allows.
And here's the thing: even if the science is equally promising, a smaller company faces skepticism.
There's an implicit bias that if this were really groundbreaking, a big player would have picked it up.
CytoDyn is stuck in this catch-22: they need more data to attract partnership or funding, but they need funding to generate that data.
Meanwhile, the clock is ticking for patients who could potentially benefit right now.
When the Pattern Becomes Lethal
I haven't seen a smoking gun document that says "we're rejecting this because you're small," but the pattern is undeniable when you look at the data.
There was a case a few years back with a small company developing a therapy for a rare pediatric cancer. They had Phase 2 data showing remarkable responses—kids who were supposed to have weeks were getting months, some even a year or more.
But they couldn't get expedited review because the FDA wanted a larger dataset. The company literally couldn't afford to enroll enough patients quickly.
Meanwhile, a major pharmaceutical company got accelerated approval for a different cancer therapy with a similar sample size and response rate within 18 months.
The small company took over four years.
By the time their therapy was approved, some of the children who could have been in early access programs had already died. Their parents testified about it later.
That's when the bias becomes lethal—it's not active malice, it's structural indifference.
The system isn't designed to ask "how do we get this to dying patients faster?" It's designed to ask "does this meet our standard process?"
And when you're small, you don't have the leverage to push back on that process or the resources to meet every demand simultaneously.
The assumption that "real" innovations come from big companies becomes a self-fulfilling prophecy because only big companies can navigate the system efficiently enough to prove their innovations work within patients' survival windows.
What a Survival-Based Urgency Pathway Would Look Like
The biggest change would be creating a separate expedited track specifically for terminal diagnoses where patients have exhausted standard options.
Here's what that would look like:
First: If you can demonstrate in Phase 2 that your therapy has a favorable safety profile and any signal of efficacy in a population with less than 18 months median survival, you get automatic fast-track designation regardless of company size.
Second: The FDA would assign a dedicated case manager to smaller companies, just like they do for major pharmaceutical players, to provide real-time guidance and prevent costly trial design mistakes.
Third: We'd shift the burden of proof for terminal patients. Instead of requiring companies to prove beyond doubt that the therapy works before any access, we'd allow conditional approval based on safety and preliminary efficacy, with the requirement to continue gathering data post-approval.
The key is recognizing that for someone with 13 months to live, the risk-benefit calculation is fundamentally different than for someone with a chronic but manageable condition.
Right now, we're applying the same standard of caution to both.
A terminal patient isn't choosing between a new therapy and perfect health—they're choosing between a new therapy and certain death.
The pathway should reflect that reality.
We'd also need mandatory response timelines—if the FDA doesn't respond to a small company's submission within 30 days for a terminal diagnosis therapy, it gets automatic escalation to senior leadership.
No more months-long waits that eat up half a patient's remaining life.
When Caution Becomes Harm
Caution becomes harm the moment it prioritizes theoretical future risks over the certainty of imminent death.
I understand the FDA's perspective—they're haunted by historical disasters like thalidomide. But we need to be honest about what we're actually protecting terminal patients from.
If someone has 13 months to live and we deny them access to a therapy with a favorable safety profile because we're worried it might only extend life by two months instead of six, or because we need another year of data to be absolutely certain—we haven't protected that patient.
We've condemned them.
They're dead either way, but in one scenario they had hope and possibly more time, and in the other they had neither.
The FDA's caution made sense when it was developed—it was designed to protect healthy people or those with manageable chronic conditions from being harmed by inadequately tested drugs.
But applying that same framework to someone who is dying creates a perverse outcome.
We're essentially saying, "We'd rather you die on schedule from your disease than risk dying slightly earlier from a therapy that might have saved you."
That's not protection. That's abandonment dressed up as prudence.
And here's what really bothers me: we already accept this logic in other contexts. We allow terminal patients to try experimental therapies through compassionate use, acknowledging that their situation is different.
But we make it so difficult, so case-by-case, that most patients never access it.
Why not systematize that recognition?
The Compassionate Use Nightmare
The reality is it's a bureaucratic nightmare that most patients don't have time for.
First, the patient's physician has to be willing to request it, which many aren't because of liability concerns or simply not knowing the process exists.
Then the company—in this case CytoDyn—has to agree to provide the drug, which for a small biotech with limited supply is a real resource question. They're trying to manufacture enough for their clinical trials, and every compassionate use case depletes that inventory.
Then you need FDA approval for single-patient access, which requires submitting an Investigational New Drug application. Even on the "emergency" track, this can take weeks.
For someone with 13 months median survival who's already exhausted standard treatments, weeks matter enormously.
But here's the cruelest part: even if you get through all that, insurance won't cover it.
The patient needs either the company to provide it free—which small biotechs often can't afford to do at scale—or the family has to pay out of pocket for the drug plus all the associated medical care and monitoring.
We're talking tens of thousands of dollars that most families don't have.
I've seen cases where patients got approval for compassionate use but couldn't actually access the therapy because of cost. You jump through all these hoops, you get the FDA to say yes, and then you still can't get the treatment.
The system is designed for exceptional cases, not as a real pathway. It's essentially a PR mechanism that lets us say "options exist" while ensuring those options remain practically inaccessible to most dying patients.
That's why we need systematic reform, not just compassionate use Band-Aids.
The Resource Gap Changes Everything
If CytoDyn had Pfizer-level resources tomorrow, we'd be looking at a completely different timeline—probably 18 to 24 months to potential approval instead of the 4 to 6 years they're currently facing.
Here's what would change immediately:
They could launch multiple Phase 3 trials simultaneously in different countries, enrolling patients much faster. Instead of scraping together funding for one trial at a time, they'd run parallel studies—one for Leronlimab as monotherapy, another for combination with checkpoint inhibitors, maybe a third exploring different dosing schedules.
That parallel approach alone cuts years off development time.
They'd hire a top-tier clinical research organization that knows exactly how to design trials the FDA wants to see the first time—no costly do-overs or protocol amendments that add months.
They'd have former FDA officials on staff who could pick up the phone and get guidance in days, not months.
They'd be running adaptive trial designs that allow them to adjust in real-time based on interim data, which the FDA is more comfortable with when you have the infrastructure to do it properly.
Most importantly, they'd have the manufacturing capacity to supply both clinical trials and a robust compassionate use program simultaneously.
Patients wouldn't have to choose between trial enrollment and individual access. They could also fund patient assistance programs to cover costs that insurance won't.
The science wouldn't change—Leronlimab's mechanism and the Phase 2 data would be exactly the same.
But the infrastructure, expertise, and financial runway to prove it definitively would compress that timeline by years.
And for women with 13-month median survival, those years are everything.
That's the inequity we're dealing with—promising science held hostage by resource constraints.
Why Big Pharma Hasn't Partnered
Big Pharma doesn't partner based solely on scientific merit—they partner based on risk-adjusted return on investment.
There are several factors working against a company like CytoDyn that have nothing to do with Leronlimab's actual potential.
First, CytoDyn has had management and execution challenges that make them a less attractive partner, regardless of their drug's promise. Big Pharma wants clean, well-executed trials and clear regulatory pathways.
If a small company has stumbled—missed endpoints, had leadership turnover, faced SEC issues—that creates partnership risk that has nothing to do with the molecule itself.
It's like refusing to buy a house with great bones because the previous owner was a messy renovator.
Second, metastatic triple negative breast cancer, while devastating, is still a relatively small market compared to blockbuster indications. Big Pharma is often looking for billion-dollar opportunities.
A therapy that might extend life by several months for a few thousand patients annually doesn't move the needle for a company doing $50 billion in revenue, even if it's transformative for those individual patients.
Third—and this is cynical but true—Big Pharma often waits for smaller companies to de-risk assets further before acquiring them.
Why pay for Phase 2 uncertainty when you can wait until Phase 3 data is in and acquire the company for less than it would cost if you factor in their desperation for capital?
It's a calculated strategy that makes business sense but leaves patients waiting.
The lack of partnership doesn't mean the science is flawed—it means the business case hasn't aligned yet.
And while those calculations are happening in boardrooms, women are dying.
Company Mistakes vs. Systemic Problems
It's both, and that's what makes this so complicated.
CytoDyn has absolutely made missteps—trial designs that didn't meet FDA expectations, communication issues with regulators, leadership decisions that raised eyebrows. Those are real problems that have delayed Leronlimab's development.
If they'd had better regulatory guidance from the start, we'd probably be further along.
But here's the thing: those missteps are often symptoms of the systemic problem, not separate from it.
When you're a small biotech operating on a shoestring budget, you can't afford the expertise that prevents those mistakes. You're making critical regulatory decisions without the benefit of former FDA officials who know exactly what the agency wants to see.
You're designing trials with limited capital, which means you might cut corners that come back to haunt you.
You're under constant pressure from investors to show progress, which can lead to overpromising or pivoting strategies too quickly.
It's like asking someone to perform surgery with inadequate training and dull instruments, then blaming them when the outcome isn't perfect.
A well-resourced company would have avoided many of CytoDyn's specific mistakes, but they'd still face the fundamental barriers—slower FDA response times, limited trial capacity, skepticism about their legitimacy.
The difference is they'd navigate those barriers more efficiently.
CytoDyn's challenges are partly self-inflicted, but the system created the conditions where those mistakes become fatal to the drug's development timeline.
A more equitable system would have safeguards to prevent promising therapies from being derailed by correctable company-level problems.
Right now, we let the therapy die with the company's mistakes, and patients pay the price.
A Therapeutic Rescue Mechanism
This would require creating what I'd call a "therapeutic rescue mechanism" within the FDA framework.
Here's how it would work:
When a therapy shows genuine promise in early trials—favorable safety profile, signals of efficacy in a serious or terminal condition—but the developing company is struggling with execution, the FDA would have authority to essentially put the asset into a form of regulatory receivership.
They'd facilitate transfer of the Investigational New Drug application to a qualified partner—either a larger pharmaceutical company, a specialized clinical research organization, or even a consortium of academic medical centers—who could take over development while compensating the original company fairly for their investment.
The key is that the therapy's development wouldn't be held hostage to one company's operational challenges.
We'd need clear triggers: maybe if a company misses critical trial endpoints twice due to design flaws, or if they can't secure funding to continue development within a certain timeframe for a designated breakthrough therapy.
At that point, the FDA could broker a transition.
This isn't about punishing small companies—it's about recognizing that patients' lives are more important than any single company's exclusive rights to develop a molecule.
Think of it like eminent domain for promising therapies in terminal diseases.
Yes, it would be controversial and we'd need strong protections against abuse, but right now we're prioritizing property rights over human lives.
If Leronlimab truly has potential to help women with metastatic triple negative breast cancer, it shouldn't matter whether CytoDyn executes perfectly—what should matter is getting that therapy evaluated properly and into patients' hands.
The current system treats the therapy and the company as inseparable, and that's a fatal flaw when time is measured in months of survival.
The Innovation Incentive Argument
That argument assumes the current system is actually incentivizing the right behavior, and I'd challenge that assumption hard.
Right now, we're incentivizing companies to hold onto assets they can't adequately develop, hoping to eventually sell them at a premium or stumble into a partnership.
That's not innovation. That's speculation.
Real innovation is getting therapies to patients who need them.
I'm not suggesting we seize assets arbitrarily or without fair compensation. This would only apply to therapies for serious or terminal conditions where the company has demonstrably failed to advance development despite showing early promise, and only after clear opportunities to correct course.
We'd build in protections—maybe the original company retains royalty rights, or gets first right of refusal to partner before any transfer happens.
The goal isn't to punish risk-taking. It's to ensure that when someone takes a risk and discovers something valuable, that value reaches patients rather than dying in developmental limbo.
And here's the thing about innovation incentives: the biggest disincentive to biotech investment right now is watching promising therapies fail not because the science was wrong, but because the company couldn't navigate the regulatory and financial maze.
Investors lose everything when that happens.
A rescue mechanism would actually protect investment by ensuring promising assets don't become total losses due to execution failures. You'd still get your return, just through a different structure.
The real question is: what are we optimizing for?
If we're optimizing for maximum company autonomy and property rights, then yes, this is radical.
But if we're optimizing for getting life-saving therapies to dying patients as quickly as possible, then letting promising drugs languish because we're afraid of disrupting business models is the truly radical position.
We've just normalized it.
What Should Happen in the Next Six Months
In the next six months, three things should happen that would make a tangible difference for patients running out of time today.
First, the FDA should grant Leronlimab breakthrough therapy designation for metastatic triple negative breast cancer. The existing Phase 2 data showing favorable safety and survival signals in a population with 13-month median survival meets the criteria. This designation would provide more frequent FDA guidance and potentially accelerate the approval timeline.
Second, CytoDyn should establish an expanded access program that goes beyond traditional compassionate use. Partner with patient advocacy groups and academic medical centers to create a structured pathway for patients who've exhausted standard options to access Leronlimab while contributing to the data collection needed for approval. Make it systematic, not exceptional.
Third, the FDA should assign a dedicated case manager to CytoDyn's Leronlimab program—the same level of support given to major pharmaceutical companies. This would prevent costly trial design mistakes, accelerate regulatory feedback loops, and ensure the company isn't navigating the approval process blind.
None of these require changing laws or creating new regulatory frameworks. They require recognizing that for women with metastatic triple negative breast cancer, six months represents nearly half their remaining life.
The system can move faster when it chooses to.
The question is whether we value procedural consistency more than we value giving dying patients a chance.
Because right now, while we're debating timelines and trial designs and partnership strategies, women are losing time they'll never get back.
Time with their families. Time to try a therapy that might give them more birthdays, more conversations, more moments.
That's not theoretical. That's happening right now.
19
